Arvinas (ARVN) Stock
Clinical stage biotech developing protein degradation therapies for cancer. Here's the price, business snapshot, and what's worth knowing about Arvinas in September 2026.
Arvinas Inc (ARVN) is a clinical-stage biotechnology company developing targeted protein degraders — molecules designed to remove disease-causing proteins rather than merely inhibit them. Its pipeline centres on programmes for hormone-driven cancers (oestrogen and androgen receptor degraders) and earlier-stage assets exploring other disease areas. With a market capitalisation of about $709.21m, Arvinas is a small-cap, research-led firm: its value is closely tied to clinical trial results, regulatory decisions and potential licensing or partnership deals. The company has secured industry collaborations that can provide funding and development expertise, but commercial success is not guaranteed. Investing in Arvinas offers exposure to a differentiated scientific platform with upside if key trials succeed, while also carrying typical biotech risks such as trial setbacks, lengthy development timelines and potential equity dilution from fundraising. This summary is educational general information only and not personalised investment advice; investors should assess suitability and risk tolerance before acting.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Arvinas' stock with a target price of $43.29, indicating strong growth potential.
Financial Health
Arvinas is performing well with strong revenue, healthy cash flow, and impressive profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory milestones can materially move the share price; outcomes are binary and timings uncertain, so expect volatility.
Platform Potential
Targeted protein degradation could broaden treatable diseases and create new medicines, though the science is still early and success is not assured.
Partner Collaborations
Industry partnerships can provide funding and development expertise, helping de‑risk programmes, but commercialisation and market uptake remain to be proven.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.